Omicron Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Beirut Lebanon (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2011
NCT01286909
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Omicron Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

prolycopene (2 trials)

Drugs in Phase 2 Trials (2)

menaquinone (vitamin k2) (3 trials)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Metabolic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3